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Aims: Treatment with liraglutide 3.0 mg has been associated with gallbladder-related adverse
events. To conduct a single-centre, double-blind, 12-week trial comparing the effect of 0.6 mg
liraglutide and steady-state liraglutide 3.0 mg with placebo on gallbladder emptying in adults
with body mass index (BMI) ≥27 kg/m2 and without diabetes.
Methods: Participants were randomized 1:1 to once-daily subcutaneous liraglutide (n = 26) or pla-
cebo (n = 26), starting at 0.6 mg with 0.6-mg weekly increments to 3.0 mg, with nutritional and
physical activity counselling. A 600-kcal (23.7 g fat) liquid meal test was performed at baseline, after
the first dose and after 12 weeks. The primary endpoint was the 12-week maximum postprandial
gallbladder ejection fraction (GBEFmax), measured over 240 minutes after starting the meal.
Results: Baseline characteristics were similar between groups (mean  SD overall age
47.6  10.0 years, BMI 32.6 3.4 kg/m2, 50% women). Mean 12-week GBEFmax (treatment
difference −3.7%, 95% confidence interval [CI] −13.1, 5.7) and area under the GBEF curve in
the first 60 minutes (−390% × min, 95% CI −919, 140) did not differ for liraglutide 3.0 mg
(n = 23) vs placebo (n = 24). The median (range) time to GBEFmax was 151 (11-240) minutes
with liraglutide 3.0 mg and 77 (22-212) minutes with placebo. Similar findings were noted after
the first 0.6-mg liraglutide dose. Gastrointestinal disorders, notably nausea and constipation,
were the most frequently reported adverse events.
Conclusions: Treatment with liraglutide did not affect the GBEFmax but appeared to prolong the
time to GBEFmax.
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1 | INTRODUCTION
Liraglutide is an analogue of the human gut incretin hormone, glucagon-
like peptide 1 (GLP-1), and belongs to the class of GLP-1 receptor agonists
(GLP-1RAs). GLP-1, predominantly secreted by intestinal L cells in
response to food intake,1,2 stimulates insulin secretion and inhibits gluca-
gon secretion in a glucose-dependent manner,1 and is known to be a
physiological regulator of appetite.3 Liraglutide promotes weight loss
through reduced appetite and energy intake.4 As an adjunct to a reduced-
calorie diet and increased physical activity, liraglutide is approved at a
dose of 3.0 mg for chronic weight management in adults with obesity or
overweight in the presence of a weight-related comorbidity.
In the weight management clinical development programme,
treatment with liraglutide 3.0 mg was associated with a greater
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frequency of gallbladder-related adverse events (predominantly chole-
lithiasis and cholecystitis) than treatment with placebo.5–8 In the larg-
est phase III trial, Satiety and Clinical Adiposity – Liraglutide Evidence
(SCALE) Obesity and Prediabetes, the proportion of participants
reporting gallbladder-related events after 56 weeks was 2.5% (3.1
events per 100 person-years of exposure) in the liraglutide group vs
1.0% (1.4 events per 100 person-years) in the placebo group.6 Partici-
pants experiencing such events generally had above-average weight
loss,6 consistent with the known risk of gallstones associated with
weight loss9; however, in the 3-year part of the trial, most weight loss
was observed during the first ~40 weeks of treatment, whereas the
incidence of gallbladder-related events remained relatively constant
over 160 weeks.5 Likewise, in the more recently published LEADER
trial, in which a mean weight loss of 2.3 kg greater than placebo was
noted with liraglutide 1.8 mg after 3 years of treatment, an imbalance
in gallbladder-related adverse events was also observed.10 This dis-
crepancy suggests that other mechanisms besides weight loss may be
involved.
An increased risk of cholelithiasis has been reported with GLP-
1RAs generally.11,12 Since these drugs have been shown to reduce
gastrointestinal motility,13 it has been suggested that GLP-1RAs may
also reduce gallbladder contraction and emptying.12 In a previous trial,
a single dose of exenatide reduced cholecystokinin (CCK)-stimulated
gallbladder emptying, in terms of the mean maximum gallbladder ejec-
tion fraction (GBEFmax), by ~40% vs placebo in healthy individuals
14;
the mean GBEFmax was 28.8% with exenatide vs 46.1% with placebo
(estimated treatment difference −17.3%). Chronic use of GLP-1RAs
could lead to impaired gallbladder contraction, resulting in the devel-
opment of biliary sludge and gallstone formation and, consequently,
an increased risk of cholelithiasis and cholecystitis.12,14
The acute effect of liraglutide 0.6 mg and chronic effects of lira-
glutide 3.0 mg on gallbladder emptying have not previously been
investigated. The primary objective of the present randomized,
double-blind trial, therefore, was to compare the effect of the first
0.6-mg dose of liraglutide and steady-state liraglutide 3.0 mg (after
12 weeks of treatment) vs placebo on postprandial gallbladder empty-
ing stimulated by a liquid meal. The trial population comprised adults
with overweight or obesity without diabetes.
2 | PARTICIPANTS AND METHODS
2.1 | Trial design
The trial was conducted at a single clinical research centre in Denmark
in accordance with the Declaration of Helsinki15 and Good Clinical
Practice guidelines,16 and was registered at ClinicalTrials.gov (identi-
fier NCT02717858). The protocol was approved by the local health
authority and independent ethics committee, and participants pro-
vided written informed consent before trial commencement.
Participants received treatment with once-daily subcutaneous lir-
aglutide or placebo, as an adjunct to nutritional and physical activity
counselling, starting at 0.6 mg and with 0.6-mg weekly increments to
3.0 mg (Figure 1). A 5% minimum weight-loss target was set, with the
aim of achieving similar weight losses in each group. To stimulate
gallbladder emptying, a liquid meal test (600 kcal, 23.7 g fat) was per-
formed at baseline, after the first 0.6-mg dose and after 12 weeks,
and was considered to be a suitable physiological stimulus.17 Gastric
emptying was also assessed in the 4-hour postprandial period of the
meal test using the paracetamol absorption technique.18
2.2 | Participants
Men or women aged between 18 and 64 years (inclusive), with a body
mass index (BMI) ≥27.0 kg/m2, stable body weight (<3 kg self-
reported change during the previous 90 days), and an ultrasound
assessment of gallbladder volume of acceptable quality (investigator
judgment) at screening were included in the trial. Key exclusion cri-
teria were: a history of gastrointestinal surgery or other medical pro-
cedures precluding a gallbladder emptying assessment (appendectomy
was allowed) or any significant digestive disease (investigator judge-
ment); a diagnosis of type 1 or 2 diabetes mellitus; a history of pancre-
atitis (acute or chronic) or any gallbladder disease (cholelithiasis,
gallbladder sludge, polyps); or pregnancy, breast-feeding and inade-
quate contraception use. Full enrolment criteria and exclusion criteria
associated with the meal test are included in Tables S1 and S2
(Supporting Information).
2.3 | Treatment and randomization
Eligible participants were randomized 1:1 to liraglutide (n = 26) or pla-
cebo (n = 26; Figure 1). Randomization codes were sent by the spon-
sor to the site in sealed units. Liraglutide and placebo were provided
in pre-filled pen-injectors (Novo Nordisk A/S, Bagsværd, Denmark).
As female hormones can influence gallbladder emptying,19 randomiza-
tion was stratified by sex. The sponsor, participants and investigators
remained blinded to treatment allocation.
2.4 | Counselling in healthy nutrition and physical
activity
During the treatment period, trial participants received five individual-
ized counselling sessions on nutrition and physical activity from a cer-
tified dietician, with a target weight loss of ≥5% of their initial body
weight over the 12-week treatment period. Participants were advised
to follow a hypocaloric diet throughout the treatment period, contain-
ing a maximum 30% of energy from fat (maximum 10% energy from
saturated fats), and ~20% from protein and ~50% from carbohydrates,
with an energy deficit of 500 kcal/d compared with the participant's
estimated total energy expenditure. If participants were unable to lose
weight after 4 weeks of treatment, more intense counselling was pro-
vided and recalculation of the recommended energy intake was
allowed to obtain a greater energy deficit than the original hypocaloric
diet. Participants who did not achieve the 5% weight-loss target were
still included in the data analyses.
Adherence to the recommended diet was at the dietician's discre-
tion. Increased physical activity was encouraged, with a goal of
60 minutes of moderate- to high-intensity physical activity per day
and a recommended >150 minutes of moderate-intensity physical
activity per week.20
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2.5 | Endpoints
During each of the three meal tests, gallbladder volume was measured
by ultrasonography in the fasted state and throughout the
240-minute period after the start of the meal, at 14 predefined time
points. Gallbladder motility endpoints were derived from the gallblad-
der volume−time curves over the 240-minute period, at baseline, after
the first 0.6-mg liraglutide dose and at steady-state liraglutide 3.0 mg
after 12 weeks. The primary endpoint was GBEFmax after 12 weeks.
Secondary endpoints related to gallbladder motility comprised:
GBEFmax after the first 0.6-mg dose; fasting gallbladder volume; area
under the GBEF−time curve 0 to 60 minutes after the start of the
meal (GBEF AUC0-60 min); time to GBEFmax (tmax); and time from tmax
to when the gallbladder had reverted to the fasting volume after the
0.6-mg dose and at steady-state after 12 weeks of treatment.
Gastric emptying endpoints were derived from the paracetamol
concentration−time curves over the same period and for the same
doses as described above: paracetamol AUC0-240 min and AUC0-60 min;
maximum paracetamol concentration (Cmax); and paracetamol tmax.
Other endpoints included change from week 0 to week 12 in
body weight and secondary safety endpoints, comprising adverse
events and changes from screening to week 12 in haematology, bio-
chemistry, including fasting lipase and amylase, calcitonin, vital signs
and physical examination. Adverse events of special medical interest
(acute gallstone disease, neoplasm and pancreatitis) had additional
data collection.
The timing of assessments is described in the Supplemental
Methods (Supporting Information).
2.6 | Estimation of gallbladder volume
Gallbladder volume during meal tests was calculated by the ellipsoid
method via ultrasound assessment of longitudinal and cross-sectional
diameters21 by a maximum of two investigators; an intra- and inter-
observer variation of <10% with respect to gallbladder volume was
achieved. Participants were in a supine position during the assess-
ment. The gallbladder was measured in three dimensions: one longitu-
dinal (D1) and two cross-sectional diameters (D2 and D3) for
calculating the volume using the formula “volume = π/6 × D1 × D2 ×
D3”.22 Fasting gallbladder volume was estimated based on the aver-
age of two sequential measurements.
2.7 | Meal test and gastric emptying
At baseline, after the first 0.6-mg dose and after 12 weeks, a 4-hour
meal test was performed in the morning after an overnight fast. The
liquid meal (250 mL of nutritional supplement drink [Nutridrink Com-
pact; Nutricia AB, Allerød, Denmark]) had a total energy content of
~600 kcal and a macronutrient composition of 35% energy from fat
(23.7 g), 16% from protein and 49% from carbohydrate.
Paracetamol (1500 mg, three effervescent 500 mg tablets) was
dissolved in 50 mL sterile water and mixed into the liquid meal (final
volume ~300 mL/340 g) for measurement of gastric emptying.23,24
The liquid meal was ingested within 10 minutes, and consumption
time standardized between meals. Before the start of the meal and for
240 minutes postprandially, the gallbladder volume was assessed and
blood samples were taken at nine predefined timepoints for the mea-
surement of paracetamol (Supplemental Methods [Supporting
Information]).
2.8 | Statistical analyses
The sample size was based on the expected precision of the estimated
difference in the primary endpoint (12-week GBEFmax) between the
two treatment groups using a two-sided 95% confidence interval
(CI) derived from the t-distribution. Based on data from a previous
study,22 the SD value for the GBEFmax following a liquid meal was cal-
culated to be 11%, with a mean GBEFmax of 71%. With 40 completing
participants in the trial and an SD of 12%, there was a probability of
≥80% for achieving a 95% CI for the true treatment difference of
GBEFmax within [d − 8.4%; d + 8.4%], where d is the estimated treat-
ment difference. The results were considered sufficiently precise to
evaluate the primary objective. To account for participants discontinu-
ing, it was planned to include 48 participants in the trial to ensure that
40 completed (assuming a drop-out rate of 20%).
All analyses were carried out on randomized individuals receiving
at least one treatment dose. The GBEF values were, for each time-
point, calculated from the gallbladder volume (as change from the
Liraglutide 3.0 mg (n=26)
Placebo (n=26)
4-week
follow-up
period
Dose
escalation
4 weeks
End of
treatment
Maintenance dose
8 weeks
Meal
test 
Randomization
(1:1) 
Nutrition and physical activity counselling
Meal
test 
Meal
test 
FIGURE 1 Trial design. Daily dosing started at 0.6 mg of treatment followed by dose escalation of 0.6 mg weekly increments to 3.0 mg. The
meal tests took place at baseline and on days 2 and 85. Screening took place 2 to 28 days before the first meal test
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fasting gallbladder volume) as: GBEF(t) = 100% × [volfasting − vol(t)]/
volfasting, where volfasting was the mean of two gallbladder volume
assessments measured within 15 minutes before the meal, and vol(t)
was the gallbladder volume measured at each timepoint, t. The pri-
mary endpoint was analysed using a linear normal model, which
included treatment and sex as factors, and baseline body weight and
baseline GBEFmax as covariates. There was no imputation for
missing data.
Additional gallbladder-related and gastric emptying endpoints
were analysed in the same way as the primary endpoint, using the cor-
responding baseline value as a covariate in the model, except that the
time to GBEFmax was summarized using descriptive statistics. Gastric
emptying endpoints were log transformed for analysis. AUCs were
calculated using the linear trapezoidal method. Body weight and
safety endpoints were summarized using descriptive statistics. Addi-
tional prespecified and exploratory analyses are described in the Sup-
plemental Methods (Supporting Information). The statistical analyses
were performed using SAS software, version 9.4 (SAS Institute, Cary,
NC, USA).
3 | RESULTS
3.1 | Participant characteristics
A total of 90 individuals were screened for eligibility, of which 34 were
screening failures. Four individuals were withdrawn prior to randomi-
zation, 2 because of protocol violations and 2 because of cholelithiasis
events, as per exclusion criteria, that were discovered by ultrasonog-
raphy before the start of the meal test. All 52 randomized individuals
were exposed to the trial drug; 5 were withdrawn after randomization,
and 47 completed the trial. In the liraglutide group, 1 withdrawal was
attributable to protocol violation and 2 participants withdrew of their
own accord; in the placebo group, 1 withdrawal was attributable to an
adverse event (migraine) and 1 was attributable to protocol violation.
All withdrawn individuals attended the follow-up visit. The trial was
conducted between March 16, 2016 and February 27, 2017.
Baseline characteristics of the trial participants were similar
between treatment groups (Table 1).
3.2 | Gallbladder motility
Figure 2 shows mean gallbladder volume (A) and ejection fraction
(B) profiles from 0 to 240 minutes after the start of the liquid meal at
baseline (before treatment initiation), after the first 0.6-mg dose, and
after 12 weeks of treatment. In each case, the gallbladder volume
decreased after meal ingestion (Figure 2A and Figure S1, Supporting
Information), and, accordingly, GBEF increased in both groups
(Figure 2B). After the first 0.6-mg dose, the mean GBEF was higher
with liraglutide than with placebo from time ~100 to ~240 minutes
and remained higher with steady-state liraglutide 3.0 mg from ~150
to ~240 minutes (Figure 2B).
After 12 weeks, the estimated mean GBEFmax (primary endpoint)
did not differ for liraglutide 3.0 mg vs placebo (Table 2). Neither was
any treatment difference observed in the estimated mean GBEFmax
after the first liraglutide 0.6-mg treatment dose. The AUC0-60 min and
fasting gallbladder volume did not differ for liraglutide vs placebo
either after the first 0.6-mg dose or with liraglutide 3.0 mg after
12 weeks of treatment. The median GBEF tmax (time to reach maxi-
mum gallbladder contraction) at baseline was 77 minutes in the lira-
glutide group vs 67 minutes in the placebo group. The median (range)
tmax increased to 104 (21-240) minutes after the first liraglutide
0.6 mg dose vs 77 (0-183) minutes with placebo and to 151 (11-240)
minutes vs 77 (22-212) minutes at steady-state (no statistical testing
was done). There was a wide variation in individual GBEF tmax values
(Figure S2, Supporting Information). More than half of the GBEF pro-
files did not return to fasting levels within the 240-minute period
(baseline: 27/52 = 52%; single dose: 33/51 = 65%; steady-state:
29/47 = 62%); therefore, the time from tmax to the time of the gall-
bladder reverting to the fasting volume was not further analysed.
3.3 | Gastric emptying
Gastric emptying was slowed after the first 0.6-mg dose of liraglutide
as compared with placebo, as indicated by significant reductions in
the paracetamol Cmax and AUC0-240 min with liraglutide, but no treat-
ment effect was seen with liraglutide 3.0 mg at week 12 (Table S3,
Supporting Information). There were no observed treatment effects
on paracetamol tmax after the first 0.6-mg dose or at steady state
(Table S3, Supporting Information). There was no apparent relation-
ship between the change in gastric emptying in the first hour of the
meal test and the change in the time to GBEFmax after the first 0.6-mg
dose or with liraglutide 3.0 mg after 12 weeks (Table S3, Supporting
Information).
3.4 | Body weight
The mean (SD) percent body weight loss after 12 weeks of treatment
was 8.2 (1.8)% in the liraglutide 3.0 mg group vs 5.5 (3.6)% in the pla-
cebo group, equivalent to −7.9 (2.1) kg vs −5.5 (3.5) kg. All participants
that completed the trial in the liraglutide group, as well as 13/24 par-
ticipants (54%) of those in the placebo group, achieved the weight-
loss goal of ≥5%. Individual changes in body weight over 12 weeks
are shown in Figure S4 (Supporting Information). There was no appar-
ent relationship between the relative change in the time to GBEFmax
and the relative change in body weight from baseline to week
12 (Figure S5, Supporting Information).
TABLE 1 Baseline demographics
Characteristic
Liraglutide 3.0 mg
(n = 26)
Placebo
(n = 26)
Total
(n = 52)
Women, n (%) 13 (50.0) 13 (50.0) 26 (50.0)
Age, years 47.6 (10.4) 47.5 (9.7) 47.6 (10.0)
Body weight, kg 98.2 (17.0) 99.8 (14.7) 99.0 (15.7)
BMI, kg/m2 32.5 (3.6) 32.6 (3.3) 32.6 (3.4)
Abbreviations: BMI, body mass index; n, number of randomized partici-
pants. Data are observed means (SD), unless otherwise stated.
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3.5 | Safety
There were no unexpected safety findings in the present trial and no
new safety concerns were raised. Overall, 138 adverse events were
reported by 25 participants (96.2%) in the liraglutide group as com-
pared with 62 events by 24 participants (92.3%) in the placebo group.
Most of the events were mild in severity (117 of the 138 events
[85%] in the liraglutide group and 46 of the 62 events [74%] in the
placebo group). As in other trials with liraglutide, the most frequently
reported adverse events were gastrointestinal disorders, with nausea
and constipation being the most commonly reported events. Overall,
23 participants (88.5%) in the liraglutide group reported 71 gastroin-
testinal events and 9 participants (34.6%) in the placebo group
reported 15 events.
One serious adverse event (lower limb fracture) was reported by
a participant in the placebo group during the follow-up period. One
non-serious, non-symptomatic cholelithiasis event was reported in the
liraglutide group. The event was discovered with ultrasonography
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FIGURE 2 A, Gallbladder volume and B, ejection fraction profiles. Data are observed means, and error bars represent the standard error of the
mean. The gallbladder ejection fraction (GBEF) values were, for each timepoint, calculated from the gallbladder volume (as change from the
fasting gallbladder volume) as: GBEF(t) = 100% × (volfasting − vol(t))/volfasting, where t = time and vol = volume
TABLE 2 Statistical analysis of gallbladder-related endpoints
Gallbladder-related endpoints
Liraglutide 0.6 mg
n = 26
Placebo
n = 25
Estimated treatment
difference (95% CI)
GBEFmax, % 71.0 72.5 −1.5 (−11.4; 8.5)
GBEF AUC0-60 min, % × min 2309 2460 −150 (−814; 514)
Fasting volume, mL 36.5 38.6 −2.1 (−8.5; 4.4)
Liraglutide 3.0 mg
n = 23
Placebo
n = 24
Estimated treatment
difference (95% CI)
GBEFmax (primary endpoint), % 70.5 74.2 −3.7 (−13.1; 5.7)
GBEF AUC0-60 min, % × min 2339 2729 −390 (−919; 140)
Fasting volume, mL 35.7 35.0 0.7 (−7.1; 8.5)
Abbreviations: AUC, area under the concentration–time curve; CI, confidence interval; GBEF, gallbladder ejection fraction; n, number of participants
included in the analysis. Data are estimated means and treatment differences.
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during the end-of-trial meal test assessment, 12 weeks after start of
treatment. No individuals in the liraglutide group discontinued the trial
as a result of adverse events vs one individual in the placebo group
who discontinued because of a worsening of migraine event 14 days
after starting treatment. No pancreatitis or neoplasm events were
reported. No clinically relevant safety findings were identified in hae-
matological or biochemical variables.
4 | DISCUSSION
This study evaluated the acute effects of a 0.6-mg liraglutide dose and
the effects with steady-state liraglutide 3.0 mg after 12 weeks of
treatment compared with placebo on postprandial gallbladder empty-
ing after a fatty liquid meal. No effects on fasting gallbladder volume,
the estimated GBEFmax or the GBEF AUC0-60 min were observed after
the first 0.6-mg dose or at steady-state with liraglutide 3.0 mg,
whereas the time to reach the maximum GBEF appeared to be later
with liraglutide than with placebo. No significant differences in the
gallbladder emptying findings were found after adjusting for weight
loss or gastric emptying in the first postprandial hour, indicating that
changes in these factors did not alter the trial conclusions.
The finding of no effect on the maximum gallbladder contraction
with liraglutide in the present trial in adults with overweight or obesity
was in contrast to results from some previous GLP-1RA trials. Reduc-
tion in CCK-induced gallbladder emptying, as observed in healthy indi-
viduals after a single dose of exenatide,14 was likewise observed after
treatment with both lixisenatide and albiglutide using similar study
designs25,26; however, in a previous 12-week trial with liraglutide in
participants with type 2 diabetes using a solid meal as stimulus for
gallbladder emptying, a similar lack of treatment effect on GBEFmax to
that observed in the present trial was noted.27 The discrepancy
between trials may partly be explained by the use of a meal to stimu-
late gallbladder emptying in the trials in which no treatment effect
was observed as compared with the use of CCK in the other trials.
Although CCK has an important role in the regulation of gallbladder
motility, several other neuroendocrine mechanisms are also involved,
and thus the meal is thought to be a more appropriate physiological
stimulus of gallbladder contraction. Differences in study populations
might also have influenced the results. Some studies have indicated
that the rate of gallbladder emptying is impaired in individuals with
type 2 diabetes compared with healthy volunteers,28,29 as well as in
obese individuals compared with those of average BMI.30,31 Female
hormones and ageing may also impair gallbladder function.19,32,33 The
GLP-1RA treatment dose (single or multiple doses) could also have an
effect, whereby tachyphylaxis of effects on gallbladder motility, as
seen with gastric emptying, may occur with a long-acting GLP-1RA
such as liraglutide, but not with short-acting GLP-1RAs such as
exenatide.27,29–31,34
In the present study, we did not observe an effect of liraglutide
on GBEFmax either after 12 weeks of treatment or after the first dose
of 0.6 mg, suggesting that the increased rate of gallbladder-related
adverse events, such as cholelithiasis, reported with liraglutide 1.8 and
3.0 mg treatment is unlikely to have been mediated by a reduced
maximum contraction of the gallbladder.5–8,10 The data suggest,
however, that the time to reach the maximum gallbladder contraction
was delayed with liraglutide treatment, indicating some effect on gall-
bladder motility. While the clinical significance of these findings is
unknown, some studies have suggested that slower ejection rates are
associated with a higher risk of the development of gallstones.12,35
The causes of gallstone formation, however, are multifactorial and
also include changes in bile composition, whereby alterations in bile
salts and cholesterol can promote gallstone formation.36,37
As weight loss is known to influence gallbladder emptying,38 a
weight loss of ≥5% at week 12 was targeted in both groups through
individualized counselling sessions. Both treatment groups achieved
the mean weight loss target; however, weight loss was greater in par-
ticipants treated with liraglutide compared with placebo (8.2% vs
5.5%, respectively). The observed delay in the time to reach the maxi-
mum gallbladder contraction was nevertheless not associated with
weight loss.
The slower rate of gastric emptying observed in the present trial
after the first 0.6-mg dose of liraglutide as compared with placebo
was not observed with steady-state liraglutide 3.0 mg after 12 weeks,
indicating tachyphylaxis. Such an effect was previously described for
GLP-1 by Nauck et al34 and confirmed by another group with a pro-
longed infusion of GLP-1.39 A recent trial with liraglutide 3.0 mg
investigating gastric emptying after a solid meal assessed by scintigra-
phy also demonstrated tachyphylaxis of liraglutide effects after 16 vs
5 weeks, although a delay in gastric emptying compared with placebo
still remained after 16 weeks.40 In the present study, changes in gall-
bladder motility were not associated with changes in gastric emptying.
No unexpected safety concerns were raised in the present trial.
As observed in other trials with liraglutide,5,41 gastrointestinal disor-
ders were the most commonly reported side effects.
A potential limitation of the present study is that the meal test
duration did not capture the full refilling of the gallbladder. It was
not possible to determine the full effect of liraglutide on gallbladder
refilling, as many of the profiles did not return to fasting levels
within the 240 minutes of the meal test. Likewise, we can only
speculate as to the effects that different meals, in particular less
fatty meals, might have had on gallbladder motility. Numerous hor-
monal interactions occur after ingestion of a high-fat meal,27,42
which may be attenuated with less fatty meals. Nevertheless, the
meal test used in the present study was considered a more appro-
priate physiological stimulus than the use of CCK infusion to stimu-
late gallbladder emptying. We used the paracetamol absorption
technique for assessing gastric emptying in the present study,
which could be considered a limitation as this method primarily
measures the gastric emptying of fluids. It was not possible to use
scintigraphy together with the meal test because of the multiple
ultrasound evaluations of the gallbladder; therefore, we found the
paracetamol absorption test more suitable.
In conclusion, treatment with 0.6 mg liraglutide or steady-state
liraglutide 3.0 mg did not affect the maximum postprandial GBEF in
this trial, but appeared to prolong the time to reach this compared
with placebo treatment, indicating some effect on gallbladder motility.
No unexpected safety concerns were identified.
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